MX392435B - Anticuerpos estables y solubles que inhiben el vegf. - Google Patents

Anticuerpos estables y solubles que inhiben el vegf.

Info

Publication number
MX392435B
MX392435B MX2017006583A MX2017006583A MX392435B MX 392435 B MX392435 B MX 392435B MX 2017006583 A MX2017006583 A MX 2017006583A MX 2017006583 A MX2017006583 A MX 2017006583A MX 392435 B MX392435 B MX 392435B
Authority
MX
Mexico
Prior art keywords
antibodies
stable
vegf
inhibit vegf
soluble antibodies
Prior art date
Application number
MX2017006583A
Other languages
English (en)
Spanish (es)
Inventor
David Urech
Leonardo Borras
Tea Gunde
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX392435B publication Critical patent/MX392435B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
MX2017006583A 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf. MX392435B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7569708P 2008-06-25 2008-06-25
US7569208P 2008-06-25 2008-06-25
US13321208P 2008-06-25 2008-06-25
US15504109P 2009-02-24 2009-02-24
PCT/CH2009/000220 WO2009155724A2 (en) 2008-06-25 2009-06-25 Stable and soluble antibodies inhibiting vegf

Publications (1)

Publication Number Publication Date
MX392435B true MX392435B (es) 2025-03-19

Family

ID=41209803

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017006583A MX392435B (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.
MX2011000011A MX2011000011A (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.
MX2013004871A MX347972B (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2011000011A MX2011000011A (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.
MX2013004871A MX347972B (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.

Country Status (26)

Country Link
US (6) US8349322B2 (https=)
EP (3) EP3216803B1 (https=)
JP (7) JP5956752B2 (https=)
KR (8) KR101817284B1 (https=)
CN (3) CN110372792A (https=)
AU (1) AU2009264565C1 (https=)
BR (1) BRPI0914251B1 (https=)
CA (2) CA2727839C (https=)
CL (1) CL2010001544A1 (https=)
CY (3) CY1118829T1 (https=)
DK (3) DK2307454T3 (https=)
ES (3) ES2793008T3 (https=)
FI (1) FI3722310T3 (https=)
HR (3) HRP20241467T1 (https=)
HU (4) HUE032894T2 (https=)
LT (4) LT3722310T (https=)
MX (3) MX392435B (https=)
NL (1) NL301058I2 (https=)
NO (1) NO2020021I1 (https=)
PH (1) PH12015501593A1 (https=)
PL (3) PL3216803T3 (https=)
PT (3) PT3722310T (https=)
RU (6) RU2588467C3 (https=)
SI (3) SI2307454T1 (https=)
WO (1) WO2009155724A2 (https=)
ZA (1) ZA201008594B (https=)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
AU2009270405B2 (en) * 2008-06-30 2014-06-05 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2010217120B2 (en) 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
EP3366692A1 (en) 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
AU2010266093B2 (en) 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
CA2815046C (en) * 2010-10-19 2019-05-14 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PL2758432T3 (pl) * 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
ES2604837T3 (es) 2012-02-02 2017-03-09 Esbatech - A Novartis Company Llc Formulación de liberación sostenida que contiene anticuerpos para administración ocular
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
KR101541478B1 (ko) 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
IL243311B (en) * 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
CN106456757A (zh) 2014-05-12 2017-02-22 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
MX2017009759A (es) * 2015-01-28 2017-10-27 Pfizer Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
US10899834B2 (en) 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
US10851399B2 (en) * 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
MY196448A (en) 2015-10-30 2023-04-12 Genentech Inc Anti-Htra1 Antibodies and Methods of use Thereof
WO2017082213A1 (ja) * 2015-11-09 2017-05-18 国立大学法人京都工芸繊維大学 ヒト血清由来ＩｇＧポリクローナル抗体の分離剤、及び、それを用いたヒト血清由来ＩｇＧポリクローナル抗体を分離する方法
CN108290004A (zh) 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
EP3377100B1 (en) 2015-11-18 2025-02-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR102293753B1 (ko) 2016-01-06 2021-08-24 오더-메이드 메디컬 리서치 인코포레이티드 Vegf 와 nrp1 의 결합을 저해하는 항체
US11007259B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. High-affinity anti-VEGF antibody
USD789171S1 (en) 2016-01-21 2017-06-13 Nomis Llc Right angle drive
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
CN113912717B (zh) * 2016-02-05 2024-05-03 得克萨斯大学体系董事会 Egfl6特异性单克隆抗体及其使用方法
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) * 2016-03-23 2017-09-27 LANXESS Deutschland GmbH Metallazopigmente
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
EP3479819B1 (en) 2016-06-30 2024-01-24 Celltrion Inc. Stable liquid pharmaceutical preparation
EP3481963B1 (en) 2016-07-08 2025-10-29 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
CA3055256A1 (en) * 2017-03-09 2018-09-13 Mab Discovery Gmbh Antibodies specifically binding to human il-1r7
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7282689B2 (ja) 2017-05-19 2023-05-29 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ リフォールディングした組み換えヒト化ラニビズマブの製造方法
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CN111770999A (zh) * 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
EP3731864A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche SA Anti-vegf antibodies and methods of use
US11078283B2 (en) 2018-01-17 2021-08-03 Apexigen, Inc. Anti-PD-L1 antibodies and methods of use
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
KR20200131839A (ko) 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
CN118846040A (zh) * 2018-04-06 2024-10-29 伊莱利利公司 用于治疗儿科患者中的癌症的雷莫芦单抗
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3109366A1 (en) * 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
PE20211602A1 (es) 2018-12-18 2021-08-18 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf
USD907455S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drive attachment
USD907456S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drill attachment
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
TW202116802A (zh) 2019-09-13 2021-05-01 瑞士商諾華公司 治療眼部疾病之方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230080224A1 (en) * 2020-02-07 2023-03-16 Agency For Science, Technology And Research Antigen-binding molecules against alppl2 and/or alpp and uses thereof
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
WO2021174127A1 (en) * 2020-02-28 2021-09-02 Apexigen, Inc. Anti-sirpa antibodies and methods of use
AU2021236302A1 (en) * 2020-03-12 2022-10-20 Immune-Onc Therapeutics, Inc. Novel anti-LILRB4 antibodies and derivative products
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
EP4157460A1 (en) 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
TW202216761A (zh) * 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
JP2023546112A (ja) 2020-10-15 2023-11-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 長時間作用型眼送達用非共有結合タンパク質－ヒアルロナンコンジュゲート
TW202237181A (zh) 2020-11-25 2022-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2022201084A1 (en) 2021-03-26 2022-09-29 Novartis Ag Methods for treating ocular diseases
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR102809807B1 (ko) 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
TW202337496A (zh) 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117820474A (zh) * 2023-04-25 2024-04-05 南京贝思奥生物科技有限公司 改善眼部血管新生相关疾病的药物及其应用
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
WO2026043906A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20260049118A1 (en) 2024-08-19 2026-02-19 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5226539A (en) 1992-06-29 1993-07-13 Cheng Lung C Pill container
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
WO1998002462A1 (en) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
WO2000053760A2 (en) * 1999-03-12 2000-09-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
KR100816621B1 (ko) * 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
PT971959E (pt) * 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU1102401A (en) * 1999-10-22 2001-05-08 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
ATE273323T1 (de) 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de) 2002-01-16 2004-09-02 Infineon Technologies Ag Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en) 2002-02-20 2003-06-10 Samsung Electronics Co., Ltd. Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
JP2006508638A (ja) 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
WO2004016740A2 (en) * 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
AU2003259718A1 (en) * 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
AU2005269265B2 (en) 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
ES2820837T3 (es) 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
US7553486B2 (en) 2006-11-13 2009-06-30 Paul Theodore Finger Anti-VEGF treatment for radiation-induced vasculopathy
HUE029445T2 (en) 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
KR101581244B1 (ko) * 2008-03-26 2015-12-31 에피토믹스, 인코포레이티드 항―ｖｅｇｆ 항체
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BRPI0914251B1 (pt) * 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
EP2769711A1 (en) * 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Methods and Compositions for Enhanced Delivery of Macromolecules
KR101721187B1 (ko) * 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
KR20200131839A (ko) 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
PE20211602A1 (es) 2018-12-18 2021-08-18 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf

Also Published As

Publication number Publication date
FI3722310T3 (fi) 2024-11-27
RU2531523C9 (ru) 2015-04-10
MX2011000011A (es) 2011-09-27
KR20180098705A (ko) 2018-09-04
US20120014958A1 (en) 2012-01-19
CY1118829T1 (el) 2018-01-10
KR102095257B1 (ko) 2020-04-01
LT2307454T (lt) 2017-05-25
NO2020021I1 (no) 2020-08-04
CA2727839A1 (en) 2009-12-30
LTC2307454I2 (lt) 2021-05-25
PL2307454T3 (pl) 2017-07-31
US8349322B2 (en) 2013-01-08
KR101817284B1 (ko) 2018-01-11
JP2015134792A (ja) 2015-07-27
DK2307454T3 (en) 2017-04-24
HRP20200814T1 (hr) 2020-08-07
ES2998307T3 (en) 2025-02-19
WO2009155724A3 (en) 2010-04-01
US10590193B2 (en) 2020-03-17
JP2019162127A (ja) 2019-09-26
RU2696972C1 (ru) 2019-08-07
RU2531523C2 (ru) 2014-10-20
LT3216803T (lt) 2020-06-10
CY2020026I2 (el) 2020-11-25
EP3216803A1 (en) 2017-09-13
EP3722310A1 (en) 2020-10-14
RU2016119152A (ru) 2017-11-21
AU2009264565A1 (en) 2009-12-30
KR102157097B1 (ko) 2020-09-18
JP2022020782A (ja) 2022-02-01
KR102296443B1 (ko) 2021-09-01
RU2011102583A (ru) 2012-07-27
KR20180005753A (ko) 2018-01-16
BRPI0914251A2 (pt) 2021-01-05
PL3216803T3 (pl) 2020-10-19
CN102143976B (zh) 2015-11-25
CY2020026I1 (el) 2020-11-25
HUE068894T2 (hu) 2025-02-28
KR20170057462A (ko) 2017-05-24
SI3216803T1 (sl) 2020-07-31
KR20150132602A (ko) 2015-11-25
CL2010001544A1 (es) 2012-02-03
US9873737B2 (en) 2018-01-23
HUE050230T2 (hu) 2020-11-30
NL301058I2 (nl) 2020-10-27
NL301058I1 (https=) 2020-07-31
ES2793008T3 (es) 2020-11-12
KR20190092630A (ko) 2019-08-07
HUS2000028I1 (hu) 2020-08-28
DK3216803T3 (da) 2020-06-02
PT3216803T (pt) 2020-06-16
RU2747735C3 (ru) 2022-05-04
BRPI0914251B1 (pt) 2022-07-19
RU2014132888A (ru) 2015-12-10
LTPA2020004I1 (lt) 2020-08-10
ES2622470T3 (es) 2017-07-06
SI2307454T1 (sl) 2017-05-31
AU2009264565C1 (en) 2022-01-27
JP7171877B6 (ja) 2024-02-06
CN104961828A (zh) 2015-10-07
CA2727839C (en) 2018-11-20
US20140004114A1 (en) 2014-01-02
HRP20241467T1 (hr) 2025-01-03
JP7171877B2 (ja) 2022-11-15
CN104961828B (zh) 2019-03-26
US20200172608A1 (en) 2020-06-04
JP6978468B2 (ja) 2021-12-08
EP2307454B1 (en) 2017-01-18
JP6821612B2 (ja) 2021-01-27
KR20160128458A (ko) 2016-11-07
MX347972B (es) 2017-05-22
PL3722310T3 (pl) 2025-01-20
KR20200108922A (ko) 2020-09-21
RU2588467C3 (ru) 2021-10-20
RU2019120079A (ru) 2020-12-28
HRP20170615T1 (hr) 2017-07-28
US12600769B2 (en) 2026-04-14
US9090684B2 (en) 2015-07-28
RU2531523C3 (ru) 2022-05-04
JP6100199B2 (ja) 2017-03-22
EP3216803B1 (en) 2020-03-11
SI3722310T1 (sl) 2025-01-31
JP2011525359A (ja) 2011-09-22
US20180072802A1 (en) 2018-03-15
HUE032894T2 (hu) 2017-11-28
PH12015501593A1 (en) 2015-12-14
JP2017055774A (ja) 2017-03-23
KR101671886B1 (ko) 2016-11-04
KR102013220B1 (ko) 2019-08-23
KR101737466B1 (ko) 2017-05-18
JP6527128B2 (ja) 2019-06-05
DK3722310T3 (da) 2024-11-18
KR20110028518A (ko) 2011-03-18
LT3722310T (lt) 2024-12-27
EP3722310B1 (en) 2024-08-28
CN102143976A (zh) 2011-08-03
CA3020290A1 (en) 2009-12-30
CN110372792A (zh) 2019-10-25
US20250066462A1 (en) 2025-02-27
JP2018108081A (ja) 2018-07-12
RU2747735C2 (ru) 2021-05-13
EP2307454A2 (en) 2011-04-13
PT2307454T (pt) 2017-04-26
RU2013133802A (ru) 2015-01-27
RU2019120079A3 (https=) 2020-12-28
JP2014158491A (ja) 2014-09-04
US20150274820A1 (en) 2015-10-01
PT3722310T (pt) 2024-11-12
AU2009264565B2 (en) 2014-05-08
RU2648152C2 (ru) 2018-03-22
WO2009155724A2 (en) 2009-12-30
CY1123028T1 (el) 2021-10-29
ZA201008594B (en) 2012-02-29
HK1150844A1 (en) 2012-01-13
JP5956752B2 (ja) 2016-07-27

Similar Documents

Publication Publication Date Title
MX392435B (es) Anticuerpos estables y solubles que inhiben el vegf.
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
UA115540C2 (uk) Антитіло до il-36r
UA115657C2 (uk) Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
UA115034C2 (uk) Імунокон'югат для застосування в лікуванні раку або запального порушення
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
JO3242B1 (ar) طرق علاج داء السكري بمستضادات dll4
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
EA202090227A1 (ru) Анти-lag-3 антитело, обладающее повышенной стабильностью
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
BR112012028326A2 (pt) anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
EA201401065A1 (ru) Ang2-связывающие молекулы
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)